litlas
Log inCreate account

Howard L. McLeod

Active 1992–2025

Also published as
Howard L McLeod
165
Papers
31,281
Citations
101
h-index
164
i10-index

Citations

Citations per year for Howard L. McLeod1993: 4 citations1994: 1 citations1995: 9 citations1996: 6 citations1997: 12 citations1998: 27 citations1999: 29 citations2000: 52 citations2001: 63 citations2002: 103 citations2003: 144 citations2004: 218 citations2005: 276 citations2006: 299 citations2007: 261 citations2008: 283 citations2009: 283 citations2010: 292 citations2011: 249 citations2012: 212 citations2013: 240 citations2014: 230 citations2015: 260 citations2016: 203 citations2017: 224 citations2018: 191 citations2019: 742 citations2020: 740 citations2021: 763 citations2022: 522 citations2023: 366 citations2024: 592 citations2025: 265 citations2026: 6 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,746 citing papers, 27.1% of this breakdownChina: 838 citing papers, 8.3% of this breakdownUnited Kingdom: 704 citing papers, 6.9% of this breakdownGermany: 433 citing papers, 4.3% of this breakdownItaly: 410 citing papers, 4% of this breakdownCanada: 388 citing papers, 3.8% of this breakdownNetherlands: 365 citing papers, 3.6% of this breakdownJapan: 333 citing papers, 3.3% of this breakdownFrance: 303 citing papers, 3% of this breakdownSpain: 260 citing papers, 2.6% of this breakdownAustralia: 250 citing papers, 2.5% of this breakdownIndia: 233 citing papers, 2.3% of this breakdown
0%27.1%Other 28.3%

Institutions

Fields

  • Medicine46.9%
  • Biochemistry, Genetics and Molecular Biology26.8%
  • Pharmacology, Toxicology and Pharmaceutics15.8%
  • Computer Science2%
  • Materials Science1.8%
  • Immunology and Microbiology1.1%
  • Other5.6%

Topics

  • Pharmacogenetics and Drug Metabolism7%
  • Colorectal Cancer Treatments and Studies2.8%
  • Drug Transport and Resistance Mechanisms2.7%
  • Computational Drug Discovery Methods2.2%
  • Cancer Genomics and Diagnostics1.8%
  • Cancer Treatment and Pharmacology1.8%
  • Other81.7%

Coauthors

All papers

Open in search
  1. Doxorubicin pathways

    Authors: Caroline F. Thorn, Connie Oshiro, Sharon Marsh, Tina Hernandez‐Boussard, Howard L. McLeod, Teri E. Klein, Russ B. Altman - Pharmacogenetics and Genomics 2010 cited by 1,614

  2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

    Authors: Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia M. Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab - Clinical Pharmacology & Therapeutics 2017 cited by 657

  3. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study

    Authors: Jacob G. Scott, Anders Berglund, Michael J. Schell, I Mihaylov, William J. Fulp, Binglin Yue, Eric A. Welsh, Jimmy J. Caudell, Kamran A. Ahmed, T. Ström, Eric A. Mellon, Puja Venkat, Peter A.S. Johnstone, John A. Foekens, Jae Lee, Eduardo G. Moros, William S. Dalton, Steven A. Eschrich, Howard L. McLeod, Louis B. Harrison, Javier F. Torres–Roca - The Lancet Oncology 2016 cited by 469

  4. PARPi treatment enhances radiotherapy-induced ferroptosis and antitumor immune responses via the cGAS signaling pathway in colorectal cancer

    Authors: Dongya Shen, Jia Luo, Ling Chen, Wenjuan Ma, Xiao‐Yuan Mao, Yu Zhang, Juyan Zheng, Yang Wang, Jielin Wan, Shiyu Wang, Jing Ouyang, Hanying Yi, Dongbo Liu, Weihua Huang, Wei Zhang, Zhaoqian Liu, Howard L. McLeod, Yijing He - Cancer Letters 2022 cited by 111

  5. Pharmacogenomics

    Authors: Dan M. Roden, Howard L. McLeod, Mary V. Relling, Marc S. Williams, George A. Mensah, Josh F. Peterson, Sara L. Van Driest - The Lancet 2019 cited by 405

  6. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study

    Authors: Nancy Gillis, Markus Ball, Qing Zhang, Zhenjun Ma, YuLong Zhao, Sean Yoder, Maria E. Balasis, Tania Mesa, David A. Sallman, Jeffrey E. Lancet, Rami S. Komrokji, Alan F. List, Howard L. McLeod, Melissa Alsina, Rachid Baz, Kenneth H. Shain, Dana E. Rollison, Eric Padron - The Lancet Oncology 2016 cited by 313

  7. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism

    Authors: Godefridus J. Peters, Harold H.J. Backus, SJ Freemantle, Baukelien van Triest, Giovanni Codacci-Pisanelli, C.L. van der Wilt, Kees Smid, John Lunec, A. Hilary Calvert, Sharon Marsh, Howard L. McLeod, Elisabeth Bloemena, Sybren L. Meijer, Gerrit Jansen, C.J. van Groeningen, Herbert M. Pinedo - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2002 cited by 430

  8. Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

    Authors: Shu‐Feng Zhou, Sui Yung Chan, Boon Cher Goh, Eli Chan, Wei Duan, Min Huang, Howard L. McLeod - Clinical Pharmacokinetics 2005 cited by 510

  9. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

    Authors: Matthew P. Goetz, Katrin Sangkuhl, Henk‐Jan Guchelaar, Matthias Schwab, Michael A. Province, Michelle Whirl‐Carrillo, W. Fraser Symmans, Howard L. McLeod, Mark J. Ratain, Hitoshi Zembutsu, Andrea Gaedigk, Ron HN van Schaik, James N. Ingle, Kelly E. Caudle, Teri E. Klein - Clinical Pharmacology & Therapeutics 2018 cited by 324

  10. Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis

    Authors: Dan Rosmarin, Claire Palles, David N. Church, Enric Domingo, Angela Jones, Elaine Johnstone, Haitao Wang, Sharon Love, Patrick Julier, Claire Scudder, George Nicholson, Anna González‐Neira, Miguel Martín, Daniel J. Sargent, Erin Green, Howard L. McLeod, Ulrich M. Zanger, Matthias Schwab, Michael Braun, Michel Seymour, Lindsay C Thompson, Benjamin Lacas, Valérie Boige, Nuria Ribelles, Shoaib Afzal, Henrik Enghusen, Søren Astrup Jensen, Marie-Christine Etienne-Grimaldi, G. Milano, Mia Wadelius, Bengt Glimelius, Hans Garmo, Milena Gusella, Thierry Lecomte, Pierre Laurent‐Puig, Eva Martinez‐Balibrea, Rohini Sharma, Jesús García‐Foncillas, Zdeněk Kleibl, Alain Morel, Jean‐Pierre Pignon, Rachel Midgley, David Kerr, Ian D. Tomlinson - Journal of Clinical Oncology 2014 cited by 259

  11. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy

    Authors: Todd C. Knepper, Meagan Montesion, Jeffery S. Russell, Ethan S. Sokol, Garrett M. Frampton, Vincent A. Miller, Lee A. Albacker, Howard L. McLeod, Zeynep Eroglu, Nikhil I. Khushalani, Vernon K. Sondak, Jane L. Messina, Michael J. Schell, James A. DeCaprio, Kenneth Y. Tsai, Andrew S. Brohl - Clinical Cancer Research 2019 cited by 170

  12. When will clinical trials finally reflect diversity?

    Authors: Todd C. Knepper, Howard L. McLeod - Nature 2018 cited by 147

  13. Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects

    Authors: William E. Evans, Howard L. McLeod - New England Journal of Medicine 2003 cited by 1,768

  14. DPYD Testing: Time to Put Patient Safety First

    Authors: Sharyn D. Baker, Susan E. Bates, Gabriel A. Brooks, William L. Dahut, Robert B. Diasio, Wafik S. El‐Deiry, William E. Evans, William D. Figg, Daniel L. Hertz, J. Kevin Hicks, Suneel Kamath, Pashtoon Murtaza Kasi, Todd C. Knepper, Howard L. McLeod, Peter H. O’Donnell, Mary V. Relling, Michelle A. Rudek, Tristan M. Sissung, D. Max Smith, Alex Sparreboom, Sandra M. Swain, Christine M. Walko - Journal of Clinical Oncology 2023 cited by 40

  15. PI3K/Akt/mTOR pathway as a target for cancer therapy

    Authors: Daniel Morgensztern, Howard L. McLeod - Anti-Cancer Drugs 2005 cited by 466

  16. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

    Authors: Laura B. Ramsey, Samuel G. Johnson, Kelly E. Caudle, Cyrine E. Haidar, Deepak Voora, Russell A. Wilke, Whitney D. Maxwell, Howard L. McLeod, Ronald M. Krauss, D M Roden, QiPing Feng, Rhonda M. Cooper‐DeHoff, Li Gong, Teri E. Klein, Mia Wadelius, Mikko Niemi - Clinical Pharmacology & Therapeutics 2014 cited by 440

  17. Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

    Authors: P. Lenzini, J. A. Johnson, Howard L. McLeod, M. J. Rieder, Brian F. Gage, L. Grosso, D. L. Veenstra, C. Eby, R. J. Glynn, D. Voora, T. Langaee, G. Grice, L. E. Farnett, Christina L. Aquilante, S. Marsh, P. M. Ridker, P. E. Milligan, A. E. Rettie, E. Deych, A. Barrett - Clinical Pharmacology & Therapeutics 2008 cited by 834

  18. Global implementation of genomic medicine: We are not alone

    Authors: Teri A. Manolio, Marc Abramowicz, Fahd Al‐Mulla, Warwick P. Anderson, Rudi Balling, Adam C. Berger, Steven B. Bleyl, Aravinda Chakravarti, Wasun Chantratita, Rex L. Chisholm, Vajira H. W. Dissanayake, Michael Dunn, Victor J. Dzau, Bok‐Ghee Han, Tim Hubbard, Anne Kolbe, Bruce R. Korf, Michiaki Kubo, Paul Lasko, Erkki Leego, Surakameth Mahasirimongkol, Partha P. Majumdar, Gert Matthijs, Howard L. McLeod, Andres Metspalu, Pierre Meulien, Satoru Miyano, Yaakov Naparstek, P. Pearl O’Rourke, George P. Patrinos, Heidi L. Rehm, Mary V. Relling, Gad Rennert, Laura Lyman Rodriguez, Dan M. Roden, Alan R. Shuldiner, Sukdeb Sinha, Patrick Tan, Mats Ulfendahl, Robyn L. Ward, Marc S. Williams, John E.L. Wong, Eric D. Green, Geoffrey S. Ginsburg - Science Translational Medicine 2015 cited by 246

  19. Strategies for enzyme/prodrug cancer therapy.

    Authors: Guo Xu, Howard L. McLeod - 2001 cited by 278

  20. Genomic Medicine: A Decade of Successes, Challenges, and Opportunities

    Authors: Jeanette McCarthy, Howard L. McLeod, Geoffrey S. Ginsburg - Science Translational Medicine 2013 cited by 245

  21. Cytochrome P450 2C9-CYP2C9

    Authors: Derek Van Booven, Sharon Marsh, Howard L. McLeod, Michelle Whirl‐Carrillo, Katrin Sangkuhl, Teri E. Klein, Russ B. Altman - Pharmacogenetics and Genomics 2010 cited by 239

  22. The National Cancer Institute Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy

    Authors: Susan G. Dorsey, Ian R. Kleckner, Debra L. Barton, Karen M. Mustian, Ann M. O’Mara, Diane St. Germain, Guido Cavaletti, Suzanne C. Danhauer, Dawn L. Hershman, Andrea G. Hohmann, Ahmet Höke, Judith O. Hopkins, Katherine Patterson Kelly, Charles L. Loprinzi, Howard L. McLeod, Supriya G. Mohile, Judith A. Paice, Julia H. Rowland, Daniela Salvemini, Rosalind A. Segal, Elizabeth Smith, Worta McCaskill Stevens, Michelle C. Janelsins - JNCI Journal of the National Cancer Institute 2019 cited by 126

  23. Genomics and Drug Response

    Authors: Liewei Wang, Howard L. McLeod, Richard M. Weinshilboum - New England Journal of Medicine 2011 cited by 614

  24. Carbamazepine, HLA-B*1502 and Risk of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: US FDA Recommendations

    Authors: P. Brent Ferrell, Howard L. McLeod - Pharmacogenomics 2008 cited by 417